Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bio-Path Holdings (BPTH)

Bio-Path Holdings (BPTH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,718
  • Shares Outstanding, K 3,692
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,600 K
  • 60-Month Beta 2.57
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.89
  • Number of Estimates 1
  • High Estimate -0.89
  • Low Estimate -0.89
  • Prior Year -0.87
  • Growth Rate Est. (year over year) -2.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.80 +5.79%
on 07/14/20
5.64 -9.96%
on 07/17/20
+0.01 (+0.16%)
since 07/02/20
3-Month
4.35 +16.78%
on 05/06/20
6.97 -27.14%
on 05/19/20
+0.41 (+8.74%)
since 05/01/20
52-Week
2.92 +73.89%
on 03/17/20
13.41 -62.12%
on 08/16/19
-8.03 (-61.27%)
since 08/02/19

Most Recent Stories

More News
Bio-Path Holdings Presents at 2020 American Society of Clinical Oncology Annual Meeting

Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 5.12 (+0.99%)
Bio-Path: 1Q Earnings Snapshot

BELLAIRE, Texas (AP) _ Bio-Path Holdings Inc. (BPTH) on Friday reported a loss of $3.3 million in its first quarter.

BPTH : 5.12 (+0.99%)
Bio-Path Holdings Reports First Quarter 2020 Financial Results

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer...

BPTH : 5.12 (+0.99%)
Bio-Path Holdings to Present at the 2020 American Society of Clinical Oncology Annual Meeting

Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer...

BPTH : 5.12 (+0.99%)
Bio-Path Holdings to Announce First Quarter 2020 Financial Results on May 15, 2020

Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer...

BPTH : 5.12 (+0.99%)
Bio-Path Holdings Presents at 2020 American Association for Cancer Research Annual Meeting

Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 5.12 (+0.99%)
Bio-Path Holdings to Present at the 2020 American Association for Cancer Research Annual Meeting

Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer...

BPTH : 5.12 (+0.99%)
Bio-Path Holdings Appoints Ernst & Young as New Auditor

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 5.12 (+0.99%)
Bio-Path Holdings Reports Full Year 2019 Financial Results

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 5.12 (+0.99%)
Bio-Path Holdings, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 6, 2020 / Bio-Path Holdings, Inc. (BPTH) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 6, 2020 at 8:30 AM Eastern...

BPTH : 5.12 (+0.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade BPTH with:

Business Summary

BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout...

See More

Key Turning Points

2nd Resistance Point 5.21
1st Resistance Point 5.14
Last Price 5.12
1st Support Level 5.03
2nd Support Level 4.98

See More

52-Week High 13.41
Fibonacci 61.8% 9.40
Fibonacci 50% 8.16
Fibonacci 38.2% 6.93
Last Price 5.12
52-Week Low 2.92

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar